Wei Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Cui has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Guoqiang Gu
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
7 shared publications- Ruiqin Xie
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
7 shared publications Haijuan Hu
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
6 shared publicationsDemin Liu
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
5 shared publicationsHongmei Zheng
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
5 shared publicationsJidong Zhang
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
4 shared publications
Latest Publications
- Open Access
- 25 April 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (6) , 5335-5344
Downregulation of microRNA‑199a‑5p attenuates hypoxia/reoxygenation‑induced cytotoxicity in cardiomyocytes by targeting the HIF‑1α‑GSK3β‑mPTP axis
MicroRNAs (miRs) have been identified as critical regulatory molecules in myocardial ischemia/reperfusion injury; however, the exact expression profile of miR‑199a‑5p in reperfusion injury and the underlying pathogenic mechanisms remain unclear. In the present study, it was revealed that miR‑199a‑5p expression was significantly increased in the plasma of patients with acute myocardial infarction and in a H9c2 cell model of oxygen‑glucose deprivation and reperfusion (OGD/R) via reverse transcription‑quantitative PCR. H9c2 cells were transfected with miR‑199a‑5p mimic or inhibitor, or short interfering RNA (siRNA) specific to hypoxia‑inducible factor‑1α (HIF‑1α). MTS, lactate dehydrogenase (LDH), TUNEL staining and flow cytometry assays were performed to determine the proliferation, LDH activity, apoptosis and mitochondrial membrane potential (ΔΨm) of H9c2 cells, respectively. The overexpression of miR‑199a‑5p in the OGD/R cell model significantly decreased the viability and increased the lactate dehydrogenase leakage of cells; whereas knockdown of miR‑199‑5p induced the opposing effects. Additionally, inhibition of miR‑199‑5p significantly attenuated OGD/R‑induced alterations to the mitochondrial transmembrane potential (ΔΨm) and increases in the apoptosis of cells. Furthermore, the overexpression or knockdown of miR‑199a‑5p decreased or increased the expression of HIF‑1α and phosphorylation of glycogen synthase kinase 3β (GSK3β) in OGD/R‑treated H9c2 cells. Additionally, siRNA‑mediated downregulation of HIF‑1α decreased phosphorylated (p)‑GSK3β (Ser9) levels and reversed the protective effects of miR‑199a‑5p inhibition on OGD/R‑injured H9c2 cells. Similarly, treatment with LiCl (a specific inhibitor of p‑GSK3β) also attenuated the protective effects of miR‑199a‑5p knockdown on OGD/R‑injured H9c2 cells. Mechanistic studies revealed that HIF‑1α was a target of miR‑199a‑5p, and that HIF‑1α downregulation suppressed the expression of p‑GSK3β in OGD/R‑injured H9c2 cells. Furthermore, an miR‑199a‑5p inhibitor increased the interaction between p‑GSK3β and adenine nucleotide transferase (ANT), which was decreased by OGD/R. Additionally, miR‑199a‑5p inhibitor reduced the OGD/R‑induced interaction between ANT and cyclophilin D (Cyp‑D), potentially leading to the increased mitochondrial membrane potential in inhibitor‑transfected OGD/R‑injured H9c2 cells. Collectively, the present study identified a novel regulatory pathway in which the upregulation of miR‑199a‑5p reduced the expression of HIF‑1α and p‑GSK3β, and potentially suppresses the interaction between p‑GSK3β and ANT, thus promoting the interaction between ANT and Cyp‑D and potentially inducing cytotoxicity in OGD/R‑injured H9c2 cells.
- 25 April 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (6) , 5335-5344
Open AccessDownregulation of microRNA‑199a‑5p attenuates hypoxia/reoxygenation‑induced cytotoxicity in cardiomyocytes by targeting the HIF‑1α‑GSK3β‑mPTP axis
MicroRNAs (miRs) have been identified as critical regulatory molecules in myocardial ischemia/reperfusion injury; however, the exact expression profile of miR‑199a‑5p in reperfusion injury and the underlying pathogenic mechanisms remain unclear. In the present study, it was revealed that miR‑199a‑5p expression was significantly increased in the plasma of patients with acute myocardial infarction and in a H9c2 cell model of oxygen‑glucose deprivation and reperfusion (OGD/R) via reverse transcription‑quantitative PCR. H9c2 cells were transfected with miR‑199a‑5p mimic or inhibitor, or short interfering RNA (siRNA) specific to hypoxia‑inducible factor‑1α (HIF‑1α). MTS, lactate dehydrogenase (LDH), TUNEL staining and flow cytometry assays were performed to determine the proliferation, LDH activity, apoptosis and mitochondrial membrane potential (ΔΨm) of H9c2 cells, respectively. The overexpression of miR‑199a‑5p in the OGD/R cell model significantly decreased the viability and increased the lactate dehydrogenase leakage of cells; whereas knockdown of miR‑199‑5p induced the opposing effects. Additionally, inhibition of miR‑199‑5p significantly attenuated OGD/R‑induced alterations to the mitochondrial transmembrane potential (ΔΨm) and increases in the apoptosis of cells. Furthermore, the overexpression or knockdown of miR‑199a‑5p decreased or increased the expression of HIF‑1α and phosphorylation of glycogen synthase kinase 3β (GSK3β) in OGD/R‑treated H9c2 cells. Additionally, siRNA‑mediated downregulation of HIF‑1α decreased phosphorylated (p)‑GSK3β (Ser9) levels and reversed the protective effects of miR‑199a‑5p inhibition on OGD/R‑injured H9c2 cells. Similarly, treatment with LiCl (a specific inhibitor of p‑GSK3β) also attenuated the protective effects of miR‑199a‑5p knockdown on OGD/R‑injured H9c2 cells. Mechanistic studies revealed that HIF‑1α was a target of miR‑199a‑5p, and that HIF‑1α downregulation suppressed the expression of p‑GSK3β in OGD/R‑injured H9c2 cells. Furthermore, an miR‑199a‑5p inhibitor increased the interaction between p‑GSK3β and adenine nucleotide transferase (ANT), which was decreased by OGD/R. Additionally, miR‑199a‑5p inhibitor reduced the OGD/R‑induced interaction between ANT and cyclophilin D (Cyp‑D), potentially leading to the increased mitochondrial membrane potential in inhibitor‑transfected OGD/R‑injured H9c2 cells. Collectively, the present study identified a novel regulatory pathway in which the upregulation of miR‑199a‑5p reduced the expression of HIF‑1α and p‑GSK3β, and potentially suppresses the interaction between p‑GSK3β and ANT, thus promoting the interaction between ANT and Cyp‑D and potentially inducing cytotoxicity in OGD/R‑injured H9c2 cells.
- Open Access
- 1 May 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (19) , e0711
Associations of common variants at ALDH2 gene and the risk of stroke in patients with coronary artery diseases undergoing percutaneous coronary intervention
Limited data are available about the role of common variants at the aldehyde dehydrogenase 2 gene (ALDH2) on the clinical outcome in Chinese patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI). In the present study, a total of 1089 patients were consecutively enrolled from January 2012 and July 2013. Six common variants at ALDH2 gene, including rs2339840, rs4648328, rs4767939, rs11066028, rs16941669, and rs671, were selected to test the associations of those polymorphisms with the cardiovascular outcome in patients with CHD after PCI. The clinical endpoints included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The composite of clinical endpoints was defined as the primary endpoint, and every endpoint alone was considered as the secondary endpoints. The median follow-up time was 38.27 months. Our results showed that the common variant rs2339840 was independently associated with a lower risk of stroke in patients with CHD after PCI (codominant model, HR = 0.32, 95% CI, 0.11–0.91, P = .074 for heterozygotes; HR = 0.25, 95% CI, 0.06–1.14, P = .033 for homozygotes; dominant model, HR = 0.32, 95% CI, 0.14–0.74, P = .007). However, no significant associations were found between other 5 single nucleotide polymorphisms (SNPs) and the clinical endpoints. For the first time, the common variant rs2339840 was reported to be a protective factor against stroke in CHD patients with PCI.
- 1 May 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (19) , e0711
Open AccessAssociations of common variants at ALDH2 gene and the risk of stroke in patients with coronary artery diseases undergoing percutaneous coronary intervention
Limited data are available about the role of common variants at the aldehyde dehydrogenase 2 gene (ALDH2) on the clinical outcome in Chinese patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI). In the present study, a total of 1089 patients were consecutively enrolled from January 2012 and July 2013. Six common variants at ALDH2 gene, including rs2339840, rs4648328, rs4767939, rs11066028, rs16941669, and rs671, were selected to test the associations of those polymorphisms with the cardiovascular outcome in patients with CHD after PCI. The clinical endpoints included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The composite of clinical endpoints was defined as the primary endpoint, and every endpoint alone was considered as the secondary endpoints. The median follow-up time was 38.27 months. Our results showed that the common variant rs2339840 was independently associated with a lower risk of stroke in patients with CHD after PCI (codominant model, HR = 0.32, 95% CI, 0.11–0.91, P = .074 for heterozygotes; HR = 0.25, 95% CI, 0.06–1.14, P = .033 for homozygotes; dominant model, HR = 0.32, 95% CI, 0.14–0.74, P = .007). However, no significant associations were found between other 5 single nucleotide polymorphisms (SNPs) and the clinical endpoints. For the first time, the common variant rs2339840 was reported to be a protective factor against stroke in CHD patients with PCI.
- Open Access
- 1 November 2017
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 11, 3179-3186
Impact of baseline blood pressure on the magnitude of blood pressure lowering by nifedipine gastrointestinal therapeutic system: refreshing the Wilder’s principle
Background: The objective of the study was to investigate the relationship between baseline blood pressure (BP) and the magnitude of BP reduction in patients with essential hypertension treated with nifedipine gastrointestinal therapeutic system (NGTS). Methods and patients: One hundred and thirty-eight patients with essential hypertension were enrolled in this prospective, single-arm, open-label study. NGTS was administered for 24 weeks to achieve target BP of 140/90 mmHg. The dose could be uptitrated to 60 mg/d in case of unsatisfactory BP reduction after 4-week treatment. Home blood pressure measurement was recorded through the initial 1–14 days, and office BP and heart rate were evaluated at 2, 4, 8, 12, and 24 weeks. Results: One hundred and seventeen patients (84.8%) completed the study, and their average BP decreased by 19.0/11.3 mmHg after 24 weeks. The reduction of either systolic or diastolic BP was positively correlated with baseline BP at weeks 2, 4, or 24 after treatment (r=0.603–0.762, all pConclusion: These findings show that BP reduction is greatly influenced by the baseline level. Patients with high baseline BP had maximum reduction after treatment with NGTS, and the maximal antihypertensive efficacy of NGTS could appear even at 4 weeks after treatment initiation.
- 1 November 2017
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 11, 3179-3186
Open AccessImpact of baseline blood pressure on the magnitude of blood pressure lowering by nifedipine gastrointestinal therapeutic system: refreshing the Wilder’s principle
Background: The objective of the study was to investigate the relationship between baseline blood pressure (BP) and the magnitude of BP reduction in patients with essential hypertension treated with nifedipine gastrointestinal therapeutic system (NGTS). Methods and patients: One hundred and thirty-eight patients with essential hypertension were enrolled in this prospective, single-arm, open-label study. NGTS was administered for 24 weeks to achieve target BP of 140/90 mmHg. The dose could be uptitrated to 60 mg/d in case of unsatisfactory BP reduction after 4-week treatment. Home blood pressure measurement was recorded through the initial 1–14 days, and office BP and heart rate were evaluated at 2, 4, 8, 12, and 24 weeks. Results: One hundred and seventeen patients (84.8%) completed the study, and their average BP decreased by 19.0/11.3 mmHg after 24 weeks. The reduction of either systolic or diastolic BP was positively correlated with baseline BP at weeks 2, 4, or 24 after treatment (r=0.603–0.762, all pConclusion: These findings show that BP reduction is greatly influenced by the baseline level. Patients with high baseline BP had maximum reduction after treatment with NGTS, and the maximal antihypertensive efficacy of NGTS could appear even at 4 weeks after treatment initiation.
- Open Access
- 1 March 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 1-8
High levels of serum β2-microglobulin predict severity of coronary artery disease
The identification of new risk factors for coronary artery disease (CAD) is increasingly sought in an effort to tackle this threatening disease. β2-microglobulin (B2M) is reported to associate with peripheral arterial disease and adverse cardiovascular outcomes. However, the association between B2M and cardiovascular disease remains under-researched. This study evaluated the effects of B2M on CAD without renal dysfunction. One thousand seven hundred sixty-two subjects (403 non-CAD subjects and 1,359 CAD subjects) were investigated. Fasting samples were collected to determine B2M level. The Gensini and SYNTAX scores were used to assess the severity of CAD. CAD subjects were significantly higher in serum B2M level comparing with non-CAD subjects (1.25 ± 0.46 vs 1.14 ± 0.28 mg/L, p < 0.001). Serum B2M level was a risk factor of CAD after adjusting potential confounders (Odds Ratio (OR) = 2.363, 95% confidence interval (CI): 1.467–3.906, p = 0.001). Receiver operating characteristics (ROC) showed B2M level moderately predicted diagnosis of CAD (the area under the ROC curve (AUC) = 0.608, 95% CI: 0.577–0.639, p < 0.001). Furthermore, serum B2M level was positively associated with Gensini score system, SYNTAX score system and the number of disease vessels (NDV ≥ 2). The significant association between serum B2M and CAD suggests that B2M could be a biomarker for CAD.
- 1 March 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 1-8
Open AccessHigh levels of serum β2-microglobulin predict severity of coronary artery disease
The identification of new risk factors for coronary artery disease (CAD) is increasingly sought in an effort to tackle this threatening disease. β2-microglobulin (B2M) is reported to associate with peripheral arterial disease and adverse cardiovascular outcomes. However, the association between B2M and cardiovascular disease remains under-researched. This study evaluated the effects of B2M on CAD without renal dysfunction. One thousand seven hundred sixty-two subjects (403 non-CAD subjects and 1,359 CAD subjects) were investigated. Fasting samples were collected to determine B2M level. The Gensini and SYNTAX scores were used to assess the severity of CAD. CAD subjects were significantly higher in serum B2M level comparing with non-CAD subjects (1.25 ± 0.46 vs 1.14 ± 0.28 mg/L, p < 0.001). Serum B2M level was a risk factor of CAD after adjusting potential confounders (Odds Ratio (OR) = 2.363, 95% confidence interval (CI): 1.467–3.906, p = 0.001). Receiver operating characteristics (ROC) showed B2M level moderately predicted diagnosis of CAD (the area under the ROC curve (AUC) = 0.608, 95% CI: 0.577–0.639, p < 0.001). Furthermore, serum B2M level was positively associated with Gensini score system, SYNTAX score system and the number of disease vessels (NDV ≥ 2). The significant association between serum B2M and CAD suggests that B2M could be a biomarker for CAD.
- Open Access
- 7 December 2016
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 45 (1) , 82-88
Effects of atorvastatin on ADP-, arachidonic acid-, collagen-, and epinephrine-induced platelet aggregation
Objective: Atorvastatin reduces the incidence of cardiovascular events. However, the effects of atorvastatin on platelet aggregation are unknown. Methods: Blood samples were obtained from 126 healthy volunteers. Prepared isolated platelet suspensions were adjusted with saline to three different concentrations of 100 × 109, 300 × 109, and 600 × 109 platelets/L. Platelet samples were incubated with atorvastatin (10−7 mol/L, 10−6 mol/L or 10−5 mol/L), and stimulated with ADP (10 µmol/L), arachidonic acid (0.5 mmol/L), collagen (2 µg/mL), and epinephrine (1 mg/mL). The maximal amplitude of aggregation and the curve slope were measured by electric impedance aggregometry. Results: Atorvastatin inhibited platelet aggregation at moderate (300 × 109/L) and high (600 × 109/L) concentrations. However, an inhibitory effect of atorvastatin at low concentrations (100 × 109/L) was not observed. Conclusions: The study shows that atorvastatin inhibits platelet aggregation in vitro, and this inhibitory effect is related to platelet concentrations.
- 7 December 2016
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 45 (1) , 82-88
Open AccessEffects of atorvastatin on ADP-, arachidonic acid-, collagen-, and epinephrine-induced platelet aggregation
Objective: Atorvastatin reduces the incidence of cardiovascular events. However, the effects of atorvastatin on platelet aggregation are unknown. Methods: Blood samples were obtained from 126 healthy volunteers. Prepared isolated platelet suspensions were adjusted with saline to three different concentrations of 100 × 109, 300 × 109, and 600 × 109 platelets/L. Platelet samples were incubated with atorvastatin (10−7 mol/L, 10−6 mol/L or 10−5 mol/L), and stimulated with ADP (10 µmol/L), arachidonic acid (0.5 mmol/L), collagen (2 µg/mL), and epinephrine (1 mg/mL). The maximal amplitude of aggregation and the curve slope were measured by electric impedance aggregometry. Results: Atorvastatin inhibited platelet aggregation at moderate (300 × 109/L) and high (600 × 109/L) concentrations. However, an inhibitory effect of atorvastatin at low concentrations (100 × 109/L) was not observed. Conclusions: The study shows that atorvastatin inhibits platelet aggregation in vitro, and this inhibitory effect is related to platelet concentrations.
- Open Access
- 1 October 2016
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 10, 3399-3406
Early intervention of long-acting nifedipine GITS reduces brachial–ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study
Early intervention of long-acting nifedipine GITS reduces brachial–ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study Jidong Zhang, Yan Wang, Haijuan Hu, Xiaohong Yang, Zejun Tian, Demin Liu, Guoqiang Gu, Hongmei Zheng, Ruiqin Xie, Wei Cui Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China Background: Nifedipine gastrointestinal therapeutic system (GITS) is used to treat angina and hypertension. The authors aimed to study the early intervention impact on arterial stiffness and pulse wave velocity (PWV) independent of its blood-pressure-(BP) lowering effect in mild hypertensive patients.Methods: This single-center, single-arm, open-label, prospective, Phase IV study recruited patients with mild hypertension and increased PWV from December 2013 to December 2014 (N=138; age, 18–75 years; systolic blood pressure, 140–160 mmHg; diastolic BP, 90–100 mmHg; increased brachial–ankle pulse wave velocity [baPWV, ≥12 m/s]). Nifedipine GITS (30 mg/d) was administered for 24 weeks to achieve target BP of
- 1 October 2016
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 10, 3399-3406
Open AccessEarly intervention of long-acting nifedipine GITS reduces brachial–ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study
Early intervention of long-acting nifedipine GITS reduces brachial–ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study Jidong Zhang, Yan Wang, Haijuan Hu, Xiaohong Yang, Zejun Tian, Demin Liu, Guoqiang Gu, Hongmei Zheng, Ruiqin Xie, Wei Cui Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China Background: Nifedipine gastrointestinal therapeutic system (GITS) is used to treat angina and hypertension. The authors aimed to study the early intervention impact on arterial stiffness and pulse wave velocity (PWV) independent of its blood-pressure-(BP) lowering effect in mild hypertensive patients.Methods: This single-center, single-arm, open-label, prospective, Phase IV study recruited patients with mild hypertension and increased PWV from December 2013 to December 2014 (N=138; age, 18–75 years; systolic blood pressure, 140–160 mmHg; diastolic BP, 90–100 mmHg; increased brachial–ankle pulse wave velocity [baPWV, ≥12 m/s]). Nifedipine GITS (30 mg/d) was administered for 24 weeks to achieve target BP of
- Open Access
- 19 August 2016
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 39 (3) , 1021-1030
Atorvastatin Protects Myocardium Against Ischemia-Reperfusion Injury Through Inhibiting miR-199a-5p
Objective: This study aimed to evaluate the protective effects of atorvastatin against myocardial ischemia/reperfusion (I/R) injury in cardiomyocytes and its possible underlying mechanism. Method : Direct cytotoxic effect of OGD/R on cardiomyocytes with and without atorvastatin pretreatment was evaluated. Effects of atorvastatin on expression of GSK-3β and miR-199a-5p were determined using RT-PCR and Western blot. In addition, GSK-3β expression with miR-199a-5p upregulation and downregulation was detected using RT-PCR, Western blot, and immunohistochemistry. Results : Pretreatment with atorvastatin significantly improved the recovery of cells viability from OGD/R (pConclusion : These results suggested that atorvastatin provides the cardioprotective effects against I/R injury via increasing GSK-3β through inhibition of miR-199a-5p.
- 19 August 2016
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 39 (3) , 1021-1030
Open AccessAtorvastatin Protects Myocardium Against Ischemia-Reperfusion Injury Through Inhibiting miR-199a-5p
Objective: This study aimed to evaluate the protective effects of atorvastatin against myocardial ischemia/reperfusion (I/R) injury in cardiomyocytes and its possible underlying mechanism. Method : Direct cytotoxic effect of OGD/R on cardiomyocytes with and without atorvastatin pretreatment was evaluated. Effects of atorvastatin on expression of GSK-3β and miR-199a-5p were determined using RT-PCR and Western blot. In addition, GSK-3β expression with miR-199a-5p upregulation and downregulation was detected using RT-PCR, Western blot, and immunohistochemistry. Results : Pretreatment with atorvastatin significantly improved the recovery of cells viability from OGD/R (pConclusion : These results suggested that atorvastatin provides the cardioprotective effects against I/R injury via increasing GSK-3β through inhibition of miR-199a-5p.
- Open Access
- 22 July 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 259
Increased prevalence of anxiety and depression symptoms in patients with coronary artery disease before and after percutaneous coronary intervention treatment
Evidence suggests that coronary heart disease (CHD) is associated with increased anxiety and a high incidence of comorbid anxiety and depression. However, the association between percutaneous coronary intervention (PCI) and comorbid anxiety and depression has not been previously investigated. This study aims to determine the relationship between PCI and anxiety and depression symptoms in CHD patients in terms of the occurrence, prone factors, and long-term outcomes of CHD. One hundred seventy CHD patients who underwent PCI treatment between September 2013 and February 2014 at the Second Hospital of Hebei Medical University were randomly selected. All patients independently completed the Hospital Anxiety and Depression Scale (HADS) and a preoperative questionnaire; they also provided details regarding their PCI-related concerns one day before PCI, as well as one day and one, three, six, and 12 months after PCI. PCI treatment was significantly associated with the symptoms of anxiety, depression, affective disorders, and comorbid anxiety and depression (χ2 = 90.18, 54.45, 101.59, 64.83; p < 0.01) at each follow-up time point. Moreover, PCI treatment was linearly correlated with each of these psychological issues (p < 0.01). The prevalence of anxiety, depression, and comorbid anxiety and depression symptoms significantly increases one day before and after PCI treatment; however, the incidence of these psychological issues significantly decreases with time following PCI. A low level of education, apprehension with regard to nursing quality, potential cardiac dysfunction, surgery sequelae, and surgery failure are also associated with a high prevalence of anxiety and depression symptoms.
- 22 July 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 259
Open AccessIncreased prevalence of anxiety and depression symptoms in patients with coronary artery disease before and after percutaneous coronary intervention treatment
Evidence suggests that coronary heart disease (CHD) is associated with increased anxiety and a high incidence of comorbid anxiety and depression. However, the association between percutaneous coronary intervention (PCI) and comorbid anxiety and depression has not been previously investigated. This study aims to determine the relationship between PCI and anxiety and depression symptoms in CHD patients in terms of the occurrence, prone factors, and long-term outcomes of CHD. One hundred seventy CHD patients who underwent PCI treatment between September 2013 and February 2014 at the Second Hospital of Hebei Medical University were randomly selected. All patients independently completed the Hospital Anxiety and Depression Scale (HADS) and a preoperative questionnaire; they also provided details regarding their PCI-related concerns one day before PCI, as well as one day and one, three, six, and 12 months after PCI. PCI treatment was significantly associated with the symptoms of anxiety, depression, affective disorders, and comorbid anxiety and depression (χ2 = 90.18, 54.45, 101.59, 64.83; p < 0.01) at each follow-up time point. Moreover, PCI treatment was linearly correlated with each of these psychological issues (p < 0.01). The prevalence of anxiety, depression, and comorbid anxiety and depression symptoms significantly increases one day before and after PCI treatment; however, the incidence of these psychological issues significantly decreases with time following PCI. A low level of education, apprehension with regard to nursing quality, potential cardiac dysfunction, surgery sequelae, and surgery failure are also associated with a high prevalence of anxiety and depression symptoms.
- 1 April 2016
- Published by Elsevier in Life Sciences
- Vol. 151, 182-188
dl -3- n -butylphthalide suppresses PDGF-BB-stimulated vascular smooth muscle cells proliferation via induction of autophagy
- 1 April 2016
- Published by Elsevier in Life Sciences
- Vol. 151, 182-188
dl -3- n -butylphthalide suppresses PDGF-BB-stimulated vascular smooth muscle cells proliferation via induction of autophagy